Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Details) - Schedule of segment reporting information, by segment

v2.4.0.8
Segment reporting (Details) - Schedule of segment reporting information, by segment (USD $)
In Thousands, unless otherwise specified
 3 Months Ended
Oct. 31, 2013
Oct. 31, 2012
Segment Reporting Information [Line Items]    
Clinical laboratory services $ 14,860 $ 15,177
Product revenues 7,663 8,434
Royalty and license fee income 1,611 2,019
Total revenues 24,134 25,630
Cost of clinical laboratory services 9,709 9,710
Cost of product revenues 3,846 4,184
Research and development 817 1,011
Selling, general and administrative 10,529 11,415
Provision for uncollectible accounts receivable 872 1,594
Legal 1,381 1,700
Operating income (loss) (3,020) (3,984)
Other 61 9
Foreign currency gain 297 229
Share-based compensation 103 142
Clinical Labs [Member] | Cost of Clinical Laboratory Services [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 2 2
Clinical Labs [Member] | Selling, General and Administrative Expenses [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 10 11
Clinical Labs [Member] | Total [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 12 13
Clinical Labs [Member]
    
Segment Reporting Information [Line Items]    
Clinical laboratory services 14,860 15,177
Total revenues 14,860 15,177
Cost of clinical laboratory services 9,709 9,710
Research and development 11 89
Selling, general and administrative 5,050 4,961
Provision for uncollectible accounts receivable 844 1,556
Legal 148 107
Total operating expenses 15,762 16,423
Operating income (loss) (902) (1,246)
Interest (11) (9)
Other 18 6
Income (loss) before income taxes (895) (1,249)
Depreciation and amortization included above 355 308
Capital expenditures 259 205
Life Sciences [Member] | Research and Development Expense [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 1 1
Life Sciences [Member] | Selling, General and Administrative Expenses [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 4  
Life Sciences [Member] | Total [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 5 1
Life Sciences [Member]
    
Segment Reporting Information [Line Items]    
Product revenues 7,663 8,434
Royalty and license fee income 1,611 2,019
Total revenues 9,274 10,453
Cost of product revenues 3,846 4,184
Research and development 526 606
Selling, general and administrative 3,495 4,272
Provision for uncollectible accounts receivable 28 38
Legal 22 6
Total operating expenses 7,917 9,106
Operating income (loss) 1,357 1,347
Interest 5 (1)
Other 27 1
Foreign currency gain 297 229
Income (loss) before income taxes 1,686 1,576
Depreciation and amortization included above 641 813
Capital expenditures 75 86
Therapeutics [Member]
    
Segment Reporting Information [Line Items]    
Research and development 280 316
Total operating expenses 280 316
Operating income (loss) (280) (316)
Income (loss) before income taxes (280) (316)
Depreciation and amortization included above 4 7
Other Segments [Member] | Selling, General and Administrative Expenses [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 86 128
Other Segments [Member] | Total [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 86 128
Other Segments [Member]
    
Segment Reporting Information [Line Items]    
Selling, general and administrative 1,984 2,182
Legal 1,211 1,587
Total operating expenses 3,195 3,769
Operating income (loss) (3,195) (3,769)
Interest (56) 1
Other 16 2
Income (loss) before income taxes (3,235) (3,766)
Depreciation and amortization included above 25 21
Consolidated [Member] | Cost of Clinical Laboratory Services [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 2 2
Consolidated [Member] | Research and Development Expense [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 1 1
Consolidated [Member] | Selling, General and Administrative Expenses [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 100 139
Consolidated [Member] | Total [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 103 142
Consolidated [Member]
    
Segment Reporting Information [Line Items]    
Clinical laboratory services 14,860 15,177
Product revenues 7,663 8,434
Royalty and license fee income 1,611 2,019
Total revenues 24,134 25,630
Cost of clinical laboratory services 9,709 9,710
Cost of product revenues 3,846 4,184
Research and development 817 1,011
Selling, general and administrative 10,529 11,415
Provision for uncollectible accounts receivable 872 1,594
Legal 1,381 1,700
Total operating expenses 27,154 29,614
Operating income (loss) (3,020) (3,984)
Interest (62) (9)
Other 61 9
Foreign currency gain 297 229
Income (loss) before income taxes (2,724) (3,755)
Depreciation and amortization included above 1,025 1,149
Capital expenditures 334 291
Cost of Clinical Laboratory Services [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 2 2
Research and Development Expense [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation 1 1
Selling, General and Administrative Expenses [Member]
    
Segment Reporting Information [Line Items]    
Share-based compensation $ 100 $ 139